Similar articles

• Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

  Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study. Coombes RC, et al. Lancet. 2007 Feb 17;369(9561):559-70. doi: 10.1016/S0140-6736(07)60200-1. Lancet. 2007. PMID: 17307102 Clinical Trial.
• A 62-year-old woman with a new diagnosis of breast cancer.

  Come SE. Come SE. JAMA. 2006 Mar 22;295(12):1434-42. doi: 10.1001/jama.295.12.1434. JAMA. 2006. PMID: 16551716 No abstract available.
• To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?

  Iddon J, Bundred NJ. Iddon J, et al. Expert Rev Anticancer Ther. 2008 Jan;8(1):9-13. doi: 10.1586/14737140.8.1.9. Expert Rev Anticancer Ther. 2008. PMID: 18095878 Review.
• Intergroup Exemestane Study mature analysis: overall survival data.

  Jassem J; International Exemestane Study Group. Jassem J, et al. Anticancer Drugs. 2008 Feb;19 Suppl 1:S3-7. doi: 10.1097/01.cad.0000277608.23376.bc. Anticancer Drugs. 2008. PMID: 18340242
• Statistical analysis in cancer clinical trials.

  Jeong JH. Jeong JH. Anticancer Drugs. 2008 Feb;19 Suppl 1:S9-10. doi: 10.1097/01.cad.0000277609.31000.10. Anticancer Drugs. 2008. PMID: 18340243 Review.